IRAP/EUROPEAN-PIRATES
A webinar on Citizen Focused Disease Prevention, organised by the Institute for Rational Drug Policies (IRAP) in cooperation with the European Pirates, established that harm reduction policies should be used to help people with a wide range of addictions, including smoking.
“We support the concept of harm reduction. Pirates emphasise the need to focus long-term attention on drug use and addictions,” said Mikuláš Peksa, Czech Green MEP. “We are working on a long-term prevention programme of minimising risks at the national level and at the European level. We must also consider how to minimise the negative impact of government drug policies and laws, and this point of view should also be followed by the European Commission.”
The European Commission currently fails to recognise the potential of harm reduction policies even though there is clear public support for them as shown by the recent Town Hall organised by the Commission on Europe's Beating Cancer Plan. Despite harm reduction being perceived by the Town Hall audience as being extremely important, the Commission still refuses to take harm reduction seriously.
According to Jindrich Voboril, Head of IRAP and former long-term National Anti-Drug Coordinator in the Czech Republic: “We have to consider harm reduction not only as a type of social or health service but as a complex approach that should also be incorporated into law and drug policies.”
Advising how to embrace harm reduction into practice: “One part of it is changing the European Commission’s structure. How can we be effective when illicit drugs are solved with one set of criteria, licit drugs with another and problem gambling is left aside altogether? The current situation does not allow effective solution to drug policies and it is hardly cost-effective. The structure of the Directorate General must be changed and the mandate of the EMCDDA (European Monitoring Centre for Drugs and Drug Addictions) must be strengthened. In the context of the ongoing debate on Europe’s Beating Cancer Plan, it’s time that the European Commission begins to take the concept of harm reduction seriously,” concluded Voboril.
“Harm reduction is a broad concept that can complement other approaches, for example when tackling addiction,” said Kasia Kowalczyk from The Global Public Health Network alongside her colleague David Mackintosh. “Harm Reduction has untapped potential across different areas of public health. It works best through a collaborative approach and engages the beneficiaries of public health services or other interventions.”
During the discussion, Hana Horka from the European Commission’s DG SANTE was not enthusiastic about harmonising approaches to addiction. Ms. Horka, despite endorsing harm reduction policies for drug addiction, did not endorse harm reduction policies for tobacco or alcohol, instead advocating for tax increases and prohibitive measures on tobacco products.
Abstinence should not be regarded as the only option for addicts. The goal of harm reduction policies is to keep people alive, help them to make positive changes in their lives and offer them alternatives that cause less harm.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom